Veradermics, Inc (MANE) stock
MANENYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 7/30
$125.64−2.41 (-1.88%)
Close on Nov 17, 2026Market cap $5.25BP/E –Yield –
Veradermics r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2025 it was $62.07M, up 166.6% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $62.07M | +166.6% |
| FY2024 | Dec 31, 2024 | $23.28M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $18.61M | – |
| Q1 FY2026 | Mar 31, 2026 | $20.93M | – |
| Q2 FY2025 | Jun 30, 2025 | $14.33M | – |
| Q1 FY2025 | Mar 31, 2025 | $11.45M | – |
See a number that looks wrong?